Evotec的股票尽管从摩根斯坦利银行和德意志银行降级,却有所上升,而HC Wainwright则保持了“买”评级。 Evotec's stock rose despite downgrades from Morgan Stanley and Deutsche Bank, while HC Wainwright maintained a "buy" rating.

在摩根斯坦利和德意志银行最近降级时, Evotec的股票在3.47美元的开张后上升到3.30美元, 而HC Wainwright则保持了“买”评级。 Evotec's stock rose to $3.30 following a $3.47 opening, amid recent downgrades from Morgan Stanley and Deutsche Bank, while HC Wainwright maintained a "buy" rating. 该公司从事各种疾病药物开发,债务与股本比率为0.42。 The company, involved in drug development for various diseases, has a debt-to-equity ratio of 0.42. 相反,EVgo报告,Q2 EPS为 - 0.10美元,超过估计数,收入增加了31.8%。 In contrast, EVgo reported a Q2 EPS of -$0.10, surpassing estimates, and saw a 31.8% revenue increase. 分析师将EVgo评为“机动购买”,目标价格为4.63美元。 Analysts rated EVgo as a "Moderate Buy" with a target price of $4.63.